Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 19, 2022

First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma: 3-Year Outcomes

Annals of Oncology


Additional Info

Annals of Oncology
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Ann. Oncol 2022 Feb 03;[EPub Ahead of Print], S Peters, A Scherpereel, R Cornelissen, Y Oulkhouir, L Greillier, MA Kaplan, T Talbot, I Monnet, S Hiret, P Baas, AK Nowak, N Fujimoto, AS Tsao, AS Mansfield, S Popat, X Zhang, N Hu, D Balli, T Spires, G Zalcman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading